olatorepatide vs RAY1225
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
olatorepatide
Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group
NCT06839664 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT07685808 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)
Result source: NCT06839664
RAY1225
Developed by Guangdong Raynovent Biotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | olatorepatide | RAY1225 |
|---|---|---|
| Body weight, % change | —Not posted · NCT06839664 | —Trial running · NCT06893016 |
| Weight loss of 5% or more | —Not posted · NCT06839664 | —Trial running · NCT06893016 |
| Weight loss of 10% or more | —Not posted · NCT06839664 | —Trial running · NCT06893016 |
| Waist circumference, change (cm) | —Not posted · NCT06839664 | —Trial running · NCT06893016 |
Body weight, % change
- olatorepatide
- —Not posted · NCT06839664
- RAY1225
- —Trial running · NCT06893016
Weight loss of 5% or more
- olatorepatide
- —Not posted · NCT06839664
- RAY1225
- —Trial running · NCT06893016
Weight loss of 10% or more
- olatorepatide
- —Not posted · NCT06839664
- RAY1225
- —Trial running · NCT06893016
Waist circumference, change (cm)
- olatorepatide
- —Not posted · NCT06839664
- RAY1225
- —Trial running · NCT06893016
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
RAY1225: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
olatorepatide
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: olatorepatide's landscape · RAY1225's landscape